P. Bossi, C. Resteghini, N. Paielli, L. Licitra, S. Pilotti et al., Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma, Oncotarget, vol.7, pp.74362-79, 2016.
DOI : 10.18632/oncotarget.11413

S. Keren, Z. Shoude, Z. Lu, and Y. Beibei, Role of EGFR as a prognostic factor for survival in head and neck cancer: a meta-analysis, Tumor Biology, vol.86, issue.11, pp.2285-95, 2014.
DOI : 10.1093/jnci/86.11.829

T. Burley, C. Martins, D. Pieve, C. Allott, L. Smith et al., Imaging EGFR in head and neck cancer: useful prognostic and treatment monitoring tool?, Eur J Nucl Med Mol Imaging, vol.43, p.231, 2016.

K. Mahoney, P. Rennert, and G. Freeman, Combination cancer immunotherapy and new immunomodulatory targets, Nature Reviews Drug Discovery, vol.133, issue.8, pp.561-84, 2015.
DOI : 10.1186/1471-2407-4-73

C. Miranda, B. Burke, R. Lee, S. Nigam, G. Clemente et al., CXCR4 chemokine receptor imaging: evaluation and validation of a new configurationally restricted tetraazamacrocyclic CXCR4 antagonist, 64Cu-CB-bicyclam, Eur J Nucl Med Mol Imaging, vol.43, p.146, 2016.

T. Vag, C. Gerngross, P. Herhaus, M. Eiber, K. Philipp-abbrederis et al., First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers, Journal of Nuclear Medicine, vol.57, issue.5, pp.741-747, 2016.
DOI : 10.2967/jnumed.115.161034

A. Leisser, M. Raderer, M. Mayerhöfer, W. Wadsak, M. Mitterhauser et al., Prospective non-invasive evaluation of CXCR4 expression for diagnosis of MALT lymphoma using 68Ga-pentixafor PET/MRI ? initial experience, Eur J Nucl Med Mol Imaging, vol.43, p.125, 2016.

M. Hekman, M. Rijpkema, P. Mulders, E. Oosterwijk, O. Boerman et al., Zirconium-89-girentuximab PET/CT imaging in renal cell carcinoma: First in man results, European Urology Supplements, vol.15, issue.12, p.39, 2016.
DOI : 10.1016/S1569-9056(16)30351-7

A. Iagaru, I. Sonni, R. Minamimoto, A. Loening, and S. Vasanawala, Ga68 RM2 PET/MRI evaluation of gastrin-releasing peptide receptor status in patients with biochemically recurrent prostate cancer and negative conventional imaging, Eur J Nucl Med Mol Imaging, vol.43, p.28, 2016.

R. Vassar, D. Kovacs, R. Yan, and P. Wong, The ??-Secretase Enzyme BACE in Health and Alzheimer's Disease: Regulation, Cell Biology, Function, and Therapeutic Potential, Journal of Neuroscience, vol.29, issue.41, pp.12787-94, 2009.
DOI : 10.1523/JNEUROSCI.3657-09.2009

D. Pearse and Z. Hughes, PDE4B as a microglia target to reduce neuroinflammation, Glia, vol.7, issue.3, pp.1698-709, 2016.
DOI : 10.1016/j.nicl.2015.01.009

H. Lashuel, C. Overk, A. Oueslati, and E. Masliah, The many faces of ??-synuclein: from structure and toxicity to therapeutic target, Nature Reviews Neuroscience, vol.418, issue.1, pp.38-48, 2013.
DOI : 10.1038/418291a

A. Takano, L. Chen, S. Nag, M. Brodney, N. Amini et al., Radio-labeling and initial evaluation of a novel beta-secretase (BACE)-selective PET radioligand, [18F]PF-06684511, in nonhuman primates, Eur J Nucl Med Mol Imaging, vol.43, p.94, 2016.

L. Chen, K. Zasadny, E. Beck, C. Chang, T. Chappie et al., In vivo evaluation of [18F]PF-06445974, a novel phosphodiesterase 4D sparing PET radioligand for the phosphodiesterase 4 enzyme, in nonhuman primates, Eur J Nucl Med Mol Imaging, vol.43, p.97, 2016.

H. Yousefi, B. Mohring, M. Arzberger, T. Höglinger, G. Wester et al., Novel compounds for specific visualization of ?-synucleinopathies by PET, Eur J Nucl Med Mol Imaging, vol.43, p.22, 2016.

H. Strauss, O. Gheysens, R. Hustinx, S. Goldman, K. Eissler et al., Safety analysis of a novel fatty acid analog 18-F FCPHA, data from a phase II study, Eur J Nucl Med Mol Imaging, vol.43, p.536, 2016.

Z. Varasteh, F. Hyafil, D. Diallo, R. Aid, N. Anizan et al., Targeting mannose receptor (MR) expressed on macrophages for imaging of atherosclerosis in a murine model using tilmanocept, Eur J Nucl Med Mol Imaging, vol.43, p.131, 2016.

G. Nagy, D. Szikra, G. Trencsényi, A. Fekete, I. Garai et al., Sc PET Imaging Agents, Angewandte Chemie International Edition, vol.11, issue.8, pp.2118-2140, 2017.
DOI : 10.1002/chem.200400799

R. Walczak, S. Krajewski, K. Szkliniarz, M. Sitarz, K. Abbas et al., Cyclotron production of 43Sc for PET imaging, EJNMMI Physics, vol.67, issue.1, p.33, 2015.
DOI : 10.1016/j.apradiso.2008.08.015
URL : https://ejnmmiphys.springeropen.com/track/pdf/10.1186/s40658-015-0136-x?site=ejnmmiphys.springeropen.com

M. Sitarz, K. Szkliniarz, R. Walczak, J. Jastrz?bski, J. Choi?ski et al., Production yield and isotopic purity of medical Sc radioisotopes formed by proton, deuteron and alpha particle beams, Eur J Nucl Med Mol Imaging, vol.43, p.200, 2016.

T. Fraum, K. Fowler, and M. J. Pet, PET/MRI:, Academic Radiology, vol.23, issue.2, pp.220-256, 2016.
DOI : 10.1016/j.acra.2015.09.008

M. Grech-sollars, K. Ordidge, B. Vaqas, L. Honeyfield, S. Khan et al., 18F-fluoromethylcholine (FMC) PET/CT and proton magnetic resonance spectroscopy; imaging and tissue biomarkers of cell membrane turnover in primary brain gliomas ? a pilot study, Eur J Nucl Med Mol Imaging, vol.43, p.195, 2016.

C. Ladefoged, D. Benoit, I. Law, S. Holm, A. Kjaer et al., Region specific optimization of continuous linear attenuation coefficients based on UTE (RESOLUTE): application to PET/MR brain imaging, Physics in Medicine and Biology, vol.60, issue.20, pp.8047-65, 2015.
DOI : 10.1088/0031-9155/60/20/8047

C. Ladefoged, I. Law, C. Hassing, L. Højgaard, and F. Andersen, The use of RESOLUTE brain attenuation correction in [18F]- fluoroethyl-tyrosine (18F-FET) PET/MRI of gliomas, Eur J Nucl Med Mol Imaging, vol.43, p.177, 2016.

I. Sonni, R. Minamimoto, V. Taviani, A. Loening, S. Gambhir et al., Imaging patients with breast and prostate cancers using combined 18F-NaF/18F-FDG and TOF simultaneous PET/MRI, Eur J Nucl Med Mol Imaging, vol.43, p.152, 2016.

M. Hartenbach, P. Baltzer, S. Hartenbach, M. Susani, C. Seitz et al., Staging primary prostate cancer with 68Ga-PSMAHBED- CC/[18F]fluorocholine-PET/MRI, Eur J Nucl Med Mol Imaging, vol.43, p.165, 2016.

R. Abgral, M. Dweck, M. Trivieri, P. Robson, N. Karakatsanis et al., Usefulness of combined FDG-PET/MR to diagnose active cardiac sarcoidosis, Eur J Nucl Med Mol Imaging, vol.43, p.61, 2016.

M. Pillai, R. Nanabala, A. Joy, A. Sasikumar, R. Knapp et al., Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer, Nuclear Medicine and Biology, vol.43, issue.11, pp.692-720, 2016.
DOI : 10.1016/j.nucmedbio.2016.08.006

C. Berliner, M. Tienken, T. Frenzel, Y. Kobayashi, A. Helberg et al., Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC, European Journal of Nuclear Medicine and Molecular Imaging, vol.16, issue.Suppl 1, pp.670-677, 2017.
DOI : 10.1186/s40644-016-0072-6

I. Einspieler, I. Rauscher, C. Düwel, M. Krönke, C. Rischpler et al., Detection efficacy of hybrid 68Ga-PSMA ligand PET/CT in prostate cancer patients with biochemical recurrence after primary radiation therapy defined by Phoenix criteria, J Nucl Med

A. Delker, W. Fendler, C. Kratochwil, A. Brunegraf, A. Gosewisch et al., Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer, European Journal of Nuclear Medicine and Molecular Imaging, vol.51, issue.1, pp.42-51, 2016.
DOI : 10.3109/0284186X.2011.618511

M. Heck, M. Retz, D. 'alessandria, C. Rauscher, I. Scheidhauer et al., Systemic Radioligand Therapy with 177Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer, The Journal of Urology, vol.196, issue.2, pp.382-91, 2016.
DOI : 10.1016/j.juro.2016.02.2969

C. Kratochwil, F. Bruchertseifer, F. Giesel, M. Weis, F. Verburg et al., 225Ac-PSMA-617 for PSMA-Targeted ??-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer, Journal of Nuclear Medicine, vol.57, issue.12, pp.1941-1945, 2016.
DOI : 10.2967/jnumed.116.178673

A. Kiess, I. Minn, G. Vaidyanathan, R. Hobbs, A. Josefsson et al., (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted ??-Particle Radiopharmaceutical Therapy, Journal of Nuclear Medicine, vol.57, issue.10, pp.1569-75, 2016.
DOI : 10.2967/jnumed.116.174300
URL : http://jnm.snmjournals.org/content/57/10/1569.full.pdf

F. Ceci, P. Castellucci, T. Graziani, C. Fonti, F. Lodi et al., CT for early restaging prostate cancer. Preliminary results of a prospective trial in patients with biochemical failure after radical therapy and PSA levels <2 ng/mL, Eur J Nucl Med Mol Imaging, vol.43, p.28, 2016.

J. Nielsen, H. Zacho, K. Dettmann, N. Landkilde, J. Jensen et al., Detection rates of 68Ga-PSMA PET/CT in patients with biochemical relapse from prostate cancer after radical prostatectomy and PSA values <1 ng/ml: preliminary results from a prospective, multicenter trial, Eur J Nucl Med Mol Imaging, vol.43, p.35, 2016.

C. Uprimny, A. Kroiss, C. Decristoforo, L. Scarpa, D. Kendler et al., Validation of 68Ga-PSMA-ligand-PET/CT in primary staging of prostate cancer patients, Eur J Nucl Med Mol Imaging, vol.43, p.138, 2016.

C. Schiller, M. Beheshti, H. Geinitz, B. Aschacher, F. Moinfar et al., CT in preoperative staging of intermediate and high risk prostate cancer patients, Eur J Nucl Med Mol Imaging, vol.43, p.167, 2016.

V. Gangemi, R. Damiano, F. Calabria, F. Barbato, and G. Cascini, Preliminary experience with Cu64PSMA PETCT in patients with intermediate and high risk prostate cancer (PC) before prostatectomy, Eur J Nucl Med Mol Imaging, vol.43, p.344, 2016.

J. Ferdinandus, E. Eppard, S. Kürpig, F. Gärtner, R. Fimmers et al., Predictors of better response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617, Eur J Nucl Med Mol Imaging, vol.43, p.212, 2016.

Z. Khurshid, H. Ahmadzadehfar, F. Gaertner, L. Papp, N. Zsótér et al., Pre-(177Lu-PSMA) therapy response prediction by textural heterogeneity parameters in 68Ga-PSMA PET scans among patients with metastatic prostate cancer, Eur J Nucl Med Mol Imaging, vol.43, p.235, 2016.

H. Kulkarni, A. Singh, and R. Baum, Differential response of bone versus lymph node metastases after Lu-177 labelled PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer, Eur J Nucl Med Mol Imaging, vol.43, p.37, 2016.

P. Kletting, D. Hardiansyah, A. Beer, and G. Glatting, Protection of normal tissue in molecular radiotherapy with 177Lu-labeled PSMAtargeting peptides using preloading, Eur J Nucl Med Mol Imaging, vol.43, issue.1, p.36, 2016.

J. Strosberg, E. Wolin, B. Chasen, M. Kulke, D. Bushnell et al., NETTER-1 phase III in patients with midgut neuroendocrine tumours treated with 177Lu-Dotatate: efficacy and safety results, Eur J Nucl Med Mol Imaging, vol.43, p.121, 2016.
DOI : 10.1093/annonc/mdw369.05

A. Mcewan, M. Wieler, M. Sawyer, D. Morrish, B. Schaitel et al., Induction and maintenance regimen with peptide receptor radionuclide therapy: Lu-177-DOTA-TATE (PRRT) improves progression free survival (PFS) in patients with advanced neuroendocrine tumours (NETs), Eur J Nucl Med Mol Imaging, vol.43, p.158, 2016.

J. Kunikowska, D. Pawlak, M. Bak, B. Kos-kudla, R. Mikolajczak et al., Tandem peptide radionuclide therapy with 90Y/177Lu- DOTATATE clinical results and long term side effect ? 10 years' experience, Eur J Nucl Med Mol Imaging, vol.43, p.121, 2016.

A. Filice, F. Fioroni, E. Grassi, A. Tartaglione, A. Fraternali et al., Can PET/CT 68Ga-DOTA-peptides uptake predict the absorbed dose in peptide receptor radionuclide therapy (PRRT)?

G. Nicolas, N. Schreiter, F. Kaul, J. Uiters, R. Mena et al., Comparison between the antagonist 68Ga- OPS202 and the agonist 68Ga-DOTATOC for somatostatin receptor PET/CT in gastroenteropancreatic NET patients: results of a phase 1/2 study, Eur J Nucl Med Mol Imaging, vol.43, p.50, 2016.

S. Dubash, N. Keat, P. Mapelli, F. Twyman, L. Carroll et al., Biodistribution, radiation dosimetry and first preliminary results of a novel 18F-fluoroethyl triazole [Tyr3] octreotate analogue for PET imaging in locally advanced and metastatic neuroendocrine tumour patients, Eur J Nucl Med Mol Imaging, vol.43, p.105, 2016.

S. Barrington, N. Mikhaeel, L. Kostakoglu, M. Meignan, M. Hutchings et al., Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group, Journal of Clinical Oncology, vol.32, issue.27, pp.3048-58, 2014.
DOI : 10.1200/JCO.2013.53.5229

S. Kanoun, A. Berriolo-riedinger, I. Tal, V. Edeline, A. Cottereau et al., Prognosis value of baseline total metabolic tumor volume (TMTV) in advanced Hodgkin lymphoma (HL): ancillary study of AHL2011 LYSA trial, Eur J Nucl Med Mol Imaging, vol.43, p.125, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01472426

C. Bailly, T. Carlier, M. Meignan, G. Crepin, C. et al., Prognosis value of FDG-PET parameters at diagnosis and after induction in patients with mantle cell lymphoma, interim results from the LyMa-PET project, a LYSA study, Eur J Nucl Med Mol Imaging, vol.43, p.202, 2016.

M. Martinez-de-bourio, A. Jimenez-ballvé, S. Arroyo, O. Serrano-palacio, A. Ortega-candil et al., Locally advanced breast cancer: utility of volumetric parameters in 18F-FDG PET/CT scans to predict recurrence and overall survival, Eur J Nucl Med Mol Imaging, vol.43, p.274, 2016.

S. Boughdad, C. Nioche, F. Orlhac, L. Champion, J. Alberini et al., Variations of FDG PET/CT SUV and textural indices in breast cancer according to metastatic status, Eur J Nucl Med Mol Imaging, vol.43, p.270, 2016.

L. Antunovic, F. Gallivanone, A. Sagona, G. Manfrinato, M. Sollini et al., Advanced 18F-FDG PET/CT imaging analysis in selected series of breast cancer patients, Eur J Nucl Med Mol Imaging, vol.43, p.75, 2016.

C. Nioche, F. Orlhac, M. Soussan, S. Boughdad, J. Alberini et al., A software for characterizing intra-tumor heterogeneity in multimodality imaging and establishing reference charts, Eur J Nucl Med Mol Imaging, vol.43, p.156, 2016.

A. Chiaravalloti, A. Fiorentini, V. Villani, C. Carapella, D. Elia et al., Overall survival and progression free survival in patients with primary brain tumors after treatment. Is 18F FDOPA PET/CT a prognostic factor in these patients, Eur J Nucl Med Mol Imaging, vol.43, p.195, 2016.

T. Skvortsova, Z. Savintseva, D. Zakhs, S. Medvedev, and N. Bechtereva, Diagnostic value of PET using [11C]methionine in suspected glioma recurrence, Eur J Nucl Med Mol Imaging, vol.43, issue.1, p.260, 2016.

E. Lopci, M. Riva, L. Olivari, F. Raneri, A. Bizzi et al., Prognostic significance of molecular and imaging biomarkers in primary brain tumors, Eur J Nucl Med Mol Imaging, vol.43, p.196, 2016.

L. Papp, T. Nakuz, H. Magometschnigg, K. Pinker, A. Haug et al., Breast cancer grading of 18F-FDG-PET/CT and patient-derived statistical features based on supervised machine-learning approaches, Eur J Nucl Med Mol Imaging, vol.43, p.75, 2016.

L. Papp, S. Hartenbach, A. Duhovic, P. Baltzer, I. Rausch et al., Evaluation of primary prostate pathologies by large-scale analysis of non-invasive PET-MRI features with machine-learning approaches, Eur J Nucl Med Mol Imaging, vol.43, p.150, 2016.

L. Papp, N. Pötsch, M. Mitterhauser, W. Wadsak, T. Beyer et al., Automated grading of glioma based on MET-PET and patientderived features utilizing multi-layer machine learning approaches, Eur J Nucl Med Mol Imaging, vol.43, p.193, 2016.

B. Garcia, M. Morales, E. Guillen, R. Figueroa, M. M. Moran et al., 11C-methionine PET/CT in multiple myeloma: comparison with 18FDG PET/CT and diagnostic value through clinical and biological parameters, Eur J Nucl Med Mol Imaging, vol.43, p.127, 2016.

L. Zanoni, A. Broccoli, A. Lambertini, C. Pellegrini, V. Stefoni et al., The role of 18F-fluorothymidine (18F-FLT) in patients with suspected lymphoma relapse, Eur J Nucl Med Mol Imaging, vol.43, p.233, 2016.

C. Parker, S. Nilsson, D. Heinrich, S. Helle, O. Sullivan et al., Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer, New England Journal of Medicine, vol.369, issue.3, pp.213-236, 2013.
DOI : 10.1056/NEJMoa1213755

H. Lee, N. Mcaddy, O. Sullivan, P. Crawley, P. Beesley et al., Radium-223 dichloride treatment for prostate cancer with bone metastases: a symptomatic outcome review of 12 months experience

G. Follacchio, V. Frantellizzi, M. Liberatore, F. Monteleone, and G. Devincentis, Pain response and acute hematologic toxicity in castration-resistant prostate cancer (CRPC) patients (pts) treated with 223Ra-dichloride: a single-center clinical series, Eur J Nucl Med Mol Imaging, vol.43, p.214, 2016.

J. Svensson, L. Hagmarker, T. Magnander, B. Wängberg, and P. Bernhardt, Radiation exposure of the spleen during 177Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume, EJNMMI Physics, vol.18, issue.Suppl 1, p.15, 2016.
DOI : 10.1016/0360-3016(90)90467-X

J. Svensson, R. Hermann, K. Holgersson, B. Wängberg, A. Sundlöv et al., Radiation exposure of the kidneys affects haematological response during 177Lu-DOTATATE treatment, Eur J Nucl Med Mol Imaging, vol.43, p.159, 2016.

V. Reijonen, J. Heikkonen, and H. Mäenpää, Can the cumulative kidney dose be predicted on the basis of the first cycle in the standard Lu- 177-octreotate treatment?, Eur J Nucl Med Mol Imaging, vol.43, p.189, 2016.